Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes.

ABSTRACT:

Context

The results of the present study demonstrate that beta cell function in newly diagnosed T2DM patients is the key predictor of response to glucose lowering medications and provides a practical tool (C-Pep120 /C-Pep0) to guide the choice of glucose lowering agent.

Objective

This work aims to identify predictors for individualization of antidiabetic therapy in patients with new-onset type 2 diabetes mellitus (T2DM).

Methods

A total of 261 drug-naive participants in the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) study, with new-onset diabetes, were randomly assigned in a single-center study to receive 1) metformin followed by glipizide and then insulin glargine on failure to achieve glycated hemoglobin A1c (HbA1c) less than

SUBMITTER: Abdelgani S 

PROVIDER: S-EPMC8787634 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature